cDNA Array Analysis of SPARC-modulated Changes in Glioma Gene Expression

[1]  S. Rempel,et al.  Molecular biology of nervous system tumors. , 2001, Hematology/oncology clinics of North America.

[2]  A. Nakeff,et al.  SPARC Modulates Cell Growth, Attachment and Migration of U87 Glioma Cells on Brain Extracellular Matrix Proteins , 2001, Journal of Neuro-Oncology.

[3]  E. Sage,et al.  SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. , 2001, The Journal of clinical investigation.

[4]  Tohru Kimura,et al.  Alteration of cell adhesion and cell cycle properties of ES cells by an inducible dominant interfering Myb mutant , 2001, Oncogene.

[5]  M. Kurrer,et al.  Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. , 2000, Cancer research.

[6]  S. Rempel,et al.  A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. , 2000, International journal of oncology.

[7]  J. Tonn,et al.  Targeting angiogenesis inhibits tumor infiltration and expression of the pro‐invasive protein SPARC , 2000, International journal of cancer.

[8]  R L Vessella,et al.  Differential expression of osteonectin/SPARC during human prostate cancer progression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  H. J. Kim,et al.  Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. , 2000, The Biochemical journal.

[10]  M. Webber,et al.  Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. , 1999, Cancer research.

[11]  T. Mikkelsen,et al.  Increased SPARC expression promotes U87 glioblastoma invasion in vitro , 1999, International Journal of Developmental Neuroscience.

[12]  E. Sage,et al.  Cell cycle‐dependent nuclear location of the matricellular protein SPARC: Association with the nuclear matrix , 1999, Journal of cellular biochemistry.

[13]  S. Rempel,et al.  SPARC: a potential diagnostic marker of invasive meningiomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  T. Mikkelsen,et al.  SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. , 1998, Journal of neuropathology and experimental neurology.

[15]  Jean-Michel,et al.  SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. , 1998, Cancer research.

[16]  J. A. Greenwood,et al.  Signaling of de‐adhesion in cellular regulation and motility , 1998, Microscopy research and technique.

[17]  X. Zhang,et al.  [The expression of plasminogen activator inhibitor-1 (PAI-1) gene in human astrocytomas]. , 1998, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[18]  E. Sage,et al.  SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[19]  B. Trask,et al.  Complete physical map of the common deletion region in Williams syndrome and identification and characterization of three novel genes , 1998, Human Genetics.

[20]  B. Nordlinger,et al.  Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  D. Greenspan,et al.  Transforming Growth Factor-β Regulation of Bone Morphogenetic Protein-1/Procollagen C-proteinase and Related Proteins in Fibrogenic Cells and Keratinocytes* , 1997, The Journal of Biological Chemistry.

[22]  A. Ullrich,et al.  Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site , 1997, Oncogene.

[23]  R. Timpl,et al.  Limited Cleavage of Extracellular Matrix Protein BM-40 by Matrix Metalloproteinases Increases Its Affinity for Collagens* , 1997, The Journal of Biological Chemistry.

[24]  O. Podhajcer,et al.  Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.

[25]  S. Coons,et al.  Dichotomy of astrocytoma migration and proliferation , 1996, International journal of cancer.

[26]  P. Chambon,et al.  Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin‐3 and BM‐40/SPARC genes , 1995, International journal of cancer.

[27]  G. Lyons,et al.  Bone morphogenetic protein-1 and a mammalian tolloid homologue (mTld) are encoded by alternatively spliced transcripts which are differentially expressed in some tissues. , 1994, The Journal of biological chemistry.

[28]  Hans Marquardt,et al.  βig-h3: A Transforming Growth Factor-β-Responsive Gene Encoding a Secreted Protein That Inhibits Cell Attachment In Vitro and Suppresses the Growth of CHO Cells in Nude Mice , 1994 .

[29]  M. Reed,et al.  Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  E. Sage,et al.  Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts , 1993, Journal of cellular physiology.

[31]  M. Iruela-Arispe,et al.  Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. , 1992, The Journal of biological chemistry.

[32]  E. Sage,et al.  SPARC antagonizes the effect of basic fibroblast growth factor on the igration of bovine aortic endothelial cells , 1992, Journal of cellular biochemistry.

[33]  R. Ross,et al.  The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Mundlos,et al.  Distribution of osteonectin mRNA and protein during human embryonic and fetal development. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[35]  E. Sage,et al.  SPARC induces the expression of type 1 plasminogen activator inhibitor in cultured bovine aortic endothelial cells. , 1991, The Journal of biological chemistry.

[36]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .